A Phase 1/2 interventional study of Pembrolizumab and Quavonlimab in Melanoma, sponsored by Merck Sharp & Dohme LLC. Completed at 36 sites in 7 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Melanoma by Merck & Co., Inc — 1 open to participants now, 6 under way, 3 of them phase 3. Melanoma · Merck & Co., Inc.
Among the 42 studies in Melanoma by Merck & Co., Inc, this one is the 23rd largest by enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2020, is one of 9 in phase 1/2, and was the 33rd registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →1 of the 42 studies in Melanoma by Merck & Co., Inc is open now, in 9 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Brazil, France and 6 more countries
Ages 6 mo–17 yrs
By country, each count listing its studies:
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 120 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 17 · Phase 3 9 · Phase 4 1
First in 1996; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 131 across the 39 interventional studies, 219 across the 2 observational. Of the 34 that completed or were terminated, 25 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 42 studies in Melanoma by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Substudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study.
The goal of substudy 02A is to evaluate the safety and efficacy of investigational treatment arms in participants with PD-1 refractory melanoma to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available.
As of Amendment 4 (effective date: 05JAN2022), a third arm has been opened to participant enrollment, treatment with pembrolizumab and all-trans retinoic acid (ATRA). Enrollment into the first two arms, treatment with pembrolizumab + quavonlimab+ vibostolimab and treatment with pembrolizumab + quavonlimab + lenvatinib has been completed per protocol as of September 2021.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
iRECIST and mRECIST
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive pembrolizumab intravenously (IV) plus quavonlimab IV plus vibostolimab IV at specified doses on specified days for a total treatment duration of up to approximately 2 years.
Biological: Pembrolizumab · Biological: Quavonlimab · Biological: Vibostolimab
Participants will receive pembrolizumab IV plus quavonlimab IV plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
Biological: Pembrolizumab · Biological: Quavonlimab · Drug: Lenvatinib
Participants will receive pembrolizumab IV plus ATRA orally at specified doses on specified days for a total treatment duration of up to approximately 2 years
Biological: Pembrolizumab · Drug: ATRA
Administered via IV infusion at a specified dose on specified days
Also known as: MK-3475, KEYTRUDA®
Administered via IV infusion at a specified dose on specified days
Also known as: MK-1308
Administered via IV infusion at a specified dose on specified days
Also known as: MK-7684
Administered via oral capsules at a specified dose on specified days
Also known as: MK-7902, LENVIMA®
Administered via oral capsules at a specified dose on specified days
Also known as: VESANOID
Percentage of Participants Who Experienced an Adverse Event (AE)
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced an AE is reported.
Time frame: Up to approximately 39 months
Percentage of Participants Who Discontinued Study Treatment Due to an AE
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinued study treatment due to an AE is reported.
Time frame: Up to 35 months
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) With 95% Confidence Interval (CI)
ORR was defined as the percentage of participants in the analysis population who have a complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters). Responses are according to RECIST 1.1 as assessed by blinded independent central review (BICR). RECIST 1.1 was modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. Per protocol, ORR with 95% CI was reported.
Time frame: Up to approximately 59 months
ORR Per RECIST 1.1 With 90% CI
ORR was defined as the percentage of participants in the analysis population who have a complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters). Responses are according to RECIST 1.1 as assessed by BICR. RECIST 1.1 was modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. Per protocol, ORR with 90% CI was reported.
Time frame: Up to approximately 59 months
Duration of Response (DOR) Per RECIST 1.1
For participants in the analysis population who showed a confirmed CR (disappearance of all target lesions) or confirmed PR (at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters), DOR was defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death due to any cause, whichever occurred first. Responses were according to RECIST 1.1 as assessed by BICR. RECIST 1.1 was modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ.
Time frame: Up to approximately 59 months
| Milestone | Pembrolizumab + Quavonlimab + Vibostolimab | Pembrolizumab + Quavonlimab + Lenvatinib | Pembrolizumab + All-trans Retinoic Acid (ATRA) |
|---|---|---|---|
| Started | 40 | 40 | 20 |
| Completed | 0 | 0 | 0 |
| Not completed | 40 | 40 | 20 |
| Withdrew: Death | 32 | 33 | 16 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Sponsor decision | 6 | 6 | 3 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced an AE is reported.
| Percentage of Participants | Pembrolizumab + Quavonlimab + Vibostolimab | Pembrolizumab + Quavonlimab + Lenvatinib | Pembrolizumab + All-trans Retinoic Acid (ATRA) |
|---|---|---|---|
| Percentage of Participants Who Experienced an Adverse Event (AE) | 97.5 | 100.0 | 95.0 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinued study treatment due to an AE is reported.
| Percentage of Participants | Pembrolizumab + Quavonlimab + Vibostolimab | Pembrolizumab + Quavonlimab + Lenvatinib | Pembrolizumab + All-trans Retinoic Acid (ATRA) |
|---|---|---|---|
| Percentage of Participants Who Discontinued Study Treatment Due to an AE | 15.0 | 30.0 | 0.0 |
ORR was defined as the percentage of participants in the analysis population who have a complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters). Responses are according to RECIST 1.1 as assessed by blinded independent central review (BICR). RECIST 1.1 was modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. Per protocol, ORR with 95% CI was reported.
| Percentage of Participants | Pembrolizumab + Quavonlimab + Vibostolimab | Pembrolizumab + Quavonlimab + Lenvatinib | Pembrolizumab + All-trans Retinoic Acid (ATRA) |
|---|---|---|---|
| Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) With 95% Confidence Interval (CI) | 17.5 (7.3 to 32.8) | 27.5 (14.6 to 43.9) | 0.0 (0.0 to 16.8) |
For participants in the analysis population who showed a confirmed CR (disappearance of all target lesions) or confirmed PR (at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters), DOR was defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death due to any cause, whichever occurred first. Responses were according to RECIST 1.1 as assessed by BICR. RECIST 1.1 was modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ.
| Months | Pembrolizumab + Quavonlimab + Vibostolimab | Pembrolizumab + Quavonlimab + Lenvatinib | Pembrolizumab + All-trans Retinoic Acid (ATRA) |
|---|---|---|---|
| Duration of Response (DOR) Per RECIST 1.1 | 9.8 (4.1 to NA) | 14.8 (3.9 to NA) | — |
ORR was defined as the percentage of participants in the analysis population who have a complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters). Responses are according to RECIST 1.1 as assessed by BICR. RECIST 1.1 was modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. Per protocol, ORR with 90% CI was reported.
| Percentage of Participants | Pembrolizumab + Quavonlimab + Vibostolimab | Pembrolizumab + Quavonlimab + Lenvatinib | Pembrolizumab + All-trans Retinoic Acid (ATRA) |
|---|---|---|---|
| ORR Per RECIST 1.1 With 90% CI | 17.5 (8.5 to 30.4) | 27.5 (16.3 to 41.4) | 0.0 (0.0 to 13.9) |
Collected over Up to approximately 59 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pembrolizumab + Quavonlimab + Vibostolimab | 32/40 (80%) | 11/40 (27.5%) | 39/40 (97.5%) |
| Pembrolizumab + Quavonlimab + Lenvatinib | 34/40 (85%) | 21/40 (52.5%) | 40/40 (100%) |
| Pembrolizumab + All-trans Retinoic Acid (ATRA) | 17/20 (85%) | 6/20 (30%) | 18/20 (90%) |
| Event | Pembrolizumab + Quavonlimab + Vibostolimab | Pembrolizumab + Quavonlimab + Lenvatinib | Pembrolizumab + All-trans Retinoic Acid (ATRA) |
|---|---|---|---|
| ColitisGastrointestinal disorders | 0/40 | 3/40 | 0/20 |
| AnaemiaBlood and lymphatic system disorders | 0/40 | 2/40 | 0/20 |
| Acute coronary syndromeCardiac disorders | 0/40 | 2/40 | 0/20 |
| Rectal haemorrhageGastrointestinal disorders | 0/40 | 0/40 | 1/20 |
| SubileusGastrointestinal disorders | 0/40 | 0/40 | 1/20 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/40 | 0/40 | 1/20 |
| Alanine aminotransferase increasedInvestigations | 1/40 | 0/40 | 1/20 |
| Aspartate aminotransferase increasedInvestigations | 0/40 | 0/40 | 1/20 |
| HeadacheNervous system disorders | 0/40 | 0/40 | 1/20 |
| Device occlusionProduct Issues | 0/40 | 0/40 | 1/20 |
| Event | Pembrolizumab + Quavonlimab + Vibostolimab | Pembrolizumab + Quavonlimab + Lenvatinib | Pembrolizumab + All-trans Retinoic Acid (ATRA) |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 11/40 | 23/40 | 2/20 |
| HeadacheNervous system disorders | 1/40 | 14/40 | 11/20 |
| HypertensionVascular disorders | 1/40 | 22/40 | 0/20 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 0/40 | 18/40 | 0/20 |
| Lipase increasedInvestigations | 3/40 | 15/40 | 1/20 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/40 | 15/40 | 4/20 |
| HypothyroidismEndocrine disorders | 2/40 | 14/40 | 0/20 |
| Dry mouthGastrointestinal disorders | 4/40 | 14/40 | 3/20 |
| Decreased appetiteMetabolism and nutrition disorders | 8/40 | 14/40 | 3/20 |
| AstheniaGeneral disorders | 13/40 | 13/40 | 4/20 |
| Age, Continuous(Years) | Pembrolizumab + Quavonlimab + Vibostolimab | Pembrolizumab + Quavonlimab + Lenvatinib | Pembrolizumab + All-trans Retinoic Acid (ATRA) | Total |
|---|---|---|---|---|
| Mean | 61.3 ± 12.9 | 60.5 ± 13.4 | 61.8 ± 16.7 | 61.1 ± 13.8 |
| Sex: Female, Male(Participants) | Pembrolizumab + Quavonlimab + Vibostolimab | Pembrolizumab + Quavonlimab + Lenvatinib | Pembrolizumab + All-trans Retinoic Acid (ATRA) | Total |
|---|---|---|---|---|
| Female | 14 | 6 | 10 | 30 |
| Male | 26 | 34 | 10 | 70 |
| Ethnicity (NIH/OMB)(Participants) | Pembrolizumab + Quavonlimab + Vibostolimab | Pembrolizumab + Quavonlimab + Lenvatinib | Pembrolizumab + All-trans Retinoic Acid (ATRA) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 | 2 |
| Not Hispanic or Latino | 28 | 26 | 18 | 72 |
| Unknown or Not Reported | 12 | 13 | 1 | 26 |
| Race (NIH/OMB)(Participants) | Pembrolizumab + Quavonlimab + Vibostolimab | Pembrolizumab + Quavonlimab + Lenvatinib | Pembrolizumab + All-trans Retinoic Acid (ATRA) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 36 | 31 | 17 | 84 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 9 | 3 | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Jun 2020 to primary completion in Aug 2025, 61 months.
Results were first posted in Aug 2026, 11 months after primary completion.
Of 135 industry-sponsored phase 1/2 interventional studies under Melanoma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 84. This study's 61 months is close to that.
Counting every sponsor, half of 220 studies reached it within 61 months; a quarter within 42 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Quavonlimab · Vibostolimab · Lenvatinib · Tretinoin